Effects of Vasodilators on CT Angiogram in Dogs with Prostatic Carcinoma
Author Information
Author(s): Griffin Maureen A., Culp William T. N., Chohan Amandeep S., Johnson Eric G., Giuffrida Michelle A., Palm Carrie A., Rebhun Robert B., Kent Michael S.
Primary Institution: University of California-Davis, School of Veterinary Medicine
Hypothesis
Vasodilator administration would result in increased prostatic arterial diameter and peak opacification on pre-PAE CTA.
Conclusion
The study found no significant difference in prostatic arterial diameter or peak opacification between pre- and post-vasodilator CTA in dogs.
Supporting Evidence
- All dogs had a MAP > 60 mmHg within 5 minutes of vasodilator bolus injection or CRI discontinuation.
- Two dogs receiving GTN IV bolus experienced an acute drop in MAP of 20 and 42 mmHg within 4 minutes post-injection.
- None of the dogs that received clevidipine CRI experienced any hypotension.
Takeaway
The study looked at how certain medicines affect blood vessels in dogs with prostate cancer, but they found that these medicines didn't really change the results.
Methodology
A prospective clinical trial was performed with 10 dogs undergoing multiphase CTA before and after IV vasodilator administration.
Limitations
The small sample size may not be adequate to detect smaller percentage differences of significance.
Participant Demographics
All dogs were castrated males with a median age of 11.1 years and median body weight of 24.7 kg.
Statistical Information
P-Value
0.052 and 0.055
Confidence Interval
95% CI 1.0% to 16.5% for left artery diameter; 95% CI -0.5% to 21.2% for right artery diameter.
Statistical Significance
p=0.052 and p=0.055
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website